Company Name True North Therapeutics
Mailing Address 951 Gateway Blvd. South San Francisco, CA 94080 USA
Company Description True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis.
Proceeds Purposes Proceeds from the financing will be used to advance True North’s lead drug candidate, TNT009, into clinical development, with the initiation of the first human clinical trial planned for early 2015.